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Multidrug-resistant organisms are a global clinical and public 
health concern.[1,2] There is an increase in the detection of 
Enterobacteriaceae strains with resistance observed against beta-
lactams, fluoroquinolones, aminoglycosides and polymyxins.[3] 
Resistance mechanisms to the beta-lactams are multifaceted and 
include outer-membrane permeability changes, upregulation of efflux 
pumps, the production of an inducible ampicillin class C (AmpC) 
beta-lactamase, and enzymes that hydrolyse the antimicrobial agent. 
Beta-lactamases are enzymes that include the cephalosporinases, 
such as the extended-spectrum beta-lactamases (ESBLs) and the 
carbapenemases, namely the metallo-beta-lactamases (MBLs), which 
consist of New Delhi MBLs (NDMs), IMPs (imipenemases) and 
VIMs (Verona integron-encoded MBLs), the Klebsiella pneumoniae 
carbapenemases (KPCs) and the oxacillinases such as OXA-48.[3]
It is important to note the difference between carbapenem-
resistant Enterobacteriaceae (CRE) and carbapenemase-producing 
Enterobacteriaceae (CPE). CRE are resistant to carbapenems due 
to carbapenemase production or via combinations of AmpC, ESBLs 
and impermeability. These multiple resistance mechanisms may play 
a role in acquiring or expressing carbapenem resistance. CPE include 
only those Enterobacteriaceae with a confirmed carbapenemase-
producing gene.[4] These genes code for the enzymes, carbapenemases, 
which are beta-lactamases that hydrolyse almost all beta-lactams 
including the carbapenems. These enzymes have been classified into 
Ambler classes A, B and D based on their amino acid sequences.[3,5] 
Class A carbapenemases include KPC and Guiana extended-spectrum 
beta-lactamase (GES), class B carbapenamases include MBLs, such 
as VIMs, NDMs and IMPs, and class D consists of OXA-48 and 
its derivatives.[6,7] Carbapenemases were initially chromosomally 
mediated (mutation within the bacterial chromosome) resulting in 
resistance in a few specific species, but the majority are now plasmid 
mediated,[8,9] resulting in horizontal transmission among various 
bacterial species and genera, i.e. transfer from one organism to 
another. As plasmids are mobile genetic elements (DNA that move 
around within the genome), their ability to acquire, harbour and 
disseminate multiple resistance genes contributes to the successful 
and aggressive transmission of resistant organisms.[10]
It is important to prevent the spread of these organisms. However, 
there are some obstacles, as clinical laboratories do not routinely 
test for CRE resistance mechanisms and are not able to differentiate 
between CRE and CPE.[11] Clinical routine laboratories make use of 
phenotypic methods that involve identification of the organism and 
antimicrobial susceptibility testing (AST). This provides the clinician 
with information on the organism causing the infection and the 
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antibiotics to which it is susceptible or resistant, but not the actual 
mechanism causing the resistance. Molecular methods (also known 
as genotypic methods) provide this additional information, as they 
identify the specific resistance genes. Another obstacle in detecting 
these organisms has been emphasised by studies showing that CPE can 
be classified as phenotypically susceptible, making their identification 
all the more challenging,[12,13] as carbapenem minimal inhibitory 
concentrations (MICs) for CPE may be below the clinical breakpoints, 
which are discriminatory antimicrobial concentrations used in the 
interpretation of results for susceptibility testing to define isolates as 
susceptible, intermediate or resistant. [14] This means that although 
a carbapenemase-producing gene may be present, phenotypic AST 
results display no resistance because routinely used automated AST 
systems cannot identify very low MICs. It is suggested that because 
the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) breakpoints are higher than those recommended by the 
Clinical and Laboratory Standards Institute (CLSI), some CPE that 
are susceptible are taken into consideration.[15-18] Currently, automated 
systems are not able to detect all types of carbapenemase producers 
reliably,[17] particularly those exhibiting low MICs, as lower MIC 
dilutions are not included in the methodology of these systems. This 
highlights the need to understand the prevalence of these organisms 
in our current setting and to establish a guide that would be useful for 
identification of the organisms for clinical management and public 
health and infection prevention and control purposes.
Objectives
We evaluated 2 678 Enterobacteriaceae isolates and correlated their 
phenotypic and genotypic profiles, with the objective of making 
recommendations for the identification and detection of CPE for both 
patient management and epidemiological and infection prevention 
and control purposes.
Methods
Organism identification and AST were performed using automated 
systems (VITEK II (bioMèrieux, France) and/or the Microflex 
MALDI-ToF (Bruker Daltonik GmbH, Germany) and the 
MicroScan Walkaway system (Siemens, USA)). The interpretation 
of susceptibility was done according to the CLSI guidelines[19] and 
the EUCAST guidelines.[20] DNA was extracted using a crude boiling 
method at 95oC for 25 minutes for cell lysis. The supernatant was 
harvested and screened for blaNDM, blaKPC, blaOXA-48 and its variants 
(OXA-162, 163, 244,  245, 247, 181, 204, 232), blaGES (GES-1-9, 11), 
blaIMP (IMP-9, 16, 18, 22, 25) and blaVIM (VIM-1-36) using a multiplex 
real-time polymerase chain reaction (LightCycler 480 II, Roche 
Diagnostics, USA), the LightCycler 480 Probes Master kit (Roche 
Diagnostics, USA) and the individual LightMix Modular kits (Roche 
Diagnostics, USA).
Ethical approval
Permission to conduct this study was obtained from the Human 
Research Ethics Committee (Medical) R14/49, University of the 
Witwatersrand, Johannesburg, South Africa (SA) (ref. no. M10464). 
General ethics approval was obtained for routine diagnostic testing, 
and patient consent was not required. No personal individual 
information was used.
Results
A total of 2 678 isolates were evaluated. Isolates were received 
as part of a referral diagnostic programme and processed in real 
time. A breakdown of the organisms isolated and specimen types 
is seen in Table 1. A total of 2 014 isolates (75.2%) harboured one 
or a combination of carbapenemases. BlaOXA-48 and its variants 
predominated (n=978, 36.5%) followed by blaNDM (n=904, 33.8%), 
blaVIM (n=108, 4.0%), blaIMP (n=35, 1.3%), blaGES (n=24, 0.9%) and 
blaKPC (n=18, 0.7%). The majority of the carbapenemase-producing 
isolates were Klebsiella spp. (n=1 459, 54.5%), driven predominantly 
by K. pneumoniae (n=1 413, 52.8%), followed by Enterobacter spp. 
(n=212, 7.9%) with E. cloacae (n=170, 6.3%) being the predominant 
species (Fig. 1). Tables 2 and 3 show the MIC breakpoint values for 
the cephalosporins and carbapenems. As observed in these tables, 
a considerable number of isolates expressing a carbapenemase or 
carbapenemases were susceptible to third- and fourth-generation 
cephalosporins and the carbapenem group of antimicrobial agents 
when the CLSI[19] and EUCAST[20] guideline clinical breakpoints 
were applied, thus indicating the number of isolates that would have 
been missed using the respective guidelines. There was no difference 
in the percentage of susceptible isolates expressing a carbapenemase 
or carbapenemases for cefotaxime, ertapenem, meropenem and 
doripenem when analysed using both guideline clinical breakpoints. 
Differences were seen with ceftazidime, which showed a 2% increase 
in the number of susceptible isolates expressing a carbapenemase 
Table 1. Distribution of organism and specimen type (N=2 678)
n (%)
Organism type
Escherichia coli 178 (6.6)
Serratia marcescens 146 (5.5)
Morganella morganii 28 (1.0)
Enterobacter aerogenes 27 (1.0)
E. asburiae 12 (0.4)
E. cancerogenus 1 (0.0)
E. cloacae 416 (15.5)
E. gergoviae 1 (0.0)
E. kobei 8 (0.3)
Enterobacter spp. 3 (0.1)
Klebsiella pneumoniae 1 685 (62.9)
K. oxytoca 30 (1.1)
Klebsiella spp. 18 (0.7)
Providencia spp. 46 ()1.7
Raoultella spp. 3 (0.1)
Proteus spp. 11 ()0.4
Citrobacter freundii 58 (2.2)
Citrobacter spp. 7 (0.3)
Specimen type
Unknown 525 (19.6)
Blood 398 (14.9)
Body fluids 142 (5.3)
Bone marrow biopsy 1 (0.0)
Catheter tip vascular 128 (4.8)
Cerebrospinal fluid 10 (0.4)
Drain 3 (0.1)
Lower respiratory tract aspirate 82 (3.1)
Sputum 91 (3.4)
Sterile site aspirate 14 (0.5)
Stool 18 (0.7)
Swabs 539 (20.1)
Tissue 55 (2.1)
Upper respiratory tract swab 16 (0.6)
Urinary catheter 34 (1.3)
Urine 622 (23.2)
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or carbapenemases using EUCAST clinical 
breakpoints, cefepime, which showed a 1% 
decrease, and imipenem, which showed a 
4% decrease. From these data it is further 
observed that although all six genes were 
present in the clinically susceptible isolates, 
the majority of these isolates were blaOXA-48 
producing.
Discussion
This study demonstrates the problems 
experienced in the detection of CPE. Overall 
75.2% of the isolates harboured at least 
one or a combination of carbapenemase-
producing genes, although a substantial 
number of isolates were phenotypically 
susceptible. The most predominant 
carbapenemase type was blaOXA-48 and its 
variants (n=978, 36.5%), followed by blaNDM 
(n=904, 33.8%), blaVIM (n=108, 4.0%), blaIMP 
(n=35, 1.3%), blaGES (n=24, 0.9%) and blaKPC 
(n=18, 0.7%). Limitations of the genotypic 
method employed should be noted; false-
negative results may have occurred because 
genes were not detected owing to the 
presence of rare carbapenemase types and/
or genetic variants that were not included 
in the screening assay, namely IMI, SPM, 
SIM, etc., suggesting that variants and other 
carbapenemases may potentially have been 
missed and that the actual proportion of 
CPE in our study population could have 
been higher. This is concerning, as the rate 
of CPE is increasing as demonstrated by the 
number of SA studies reporting occurrences 
and outbreaks.[13,21-25]
The majority of the carbapenemase-
producing isolates were K. pneumoniae 
(n=1 413, 52.8%), followed by E. cloacae 
(n=170, 6.3%). Carbapenem resistance is 
particularly worrying in intrinsically coli-
stin-resistant organisms such as Serratia 
marcescens, Providencia spp. and Morganella 
morganii, which harboured carbapenemases 
in 124 (4.6%), 47 (1.8%) and 12 (0.5%) 
isolates, respectively, and accounted for 6.3% 
of all isolates. Treatment options for patients 
infected with these isolates are limited, with 
most conventional treatment options being 
exhausted.
A considerable number of isolates 
producing a phenotypically susceptible 
profile to the third- and fourth-generation 
cephalosporins and carbapenems expressed 
carbapenemases. The numbers varied 
per antimicrobial agent (Tables 2 and 3), 
but were relatively high. Difficulties in 
identifying metallo-beta-carbapenemase-
producing organisms primarily based on 
MIC results have been reported previously. [12] 
The most striking carbapenemase type in 
our study was OXA-48 and its variants. 
This is not surprising, as this genotype has 
an atypical hydrolysis profile and clinical 
isolates harbouring this gene rarely show the 
resistance phenotype that is attributable to the 
expression of carbapenemases alone, often 
expressing other beta-lactamases such as the 
ESBLs, resulting in an extensive resistance 
profile.[17] However, intermediate resistance 
and susceptibility to carbapenems have been 
observed in various carbapenemase type-
producing Enterobacteriaceae, particularly 
OXA-48/OXA181-producing isolates that 
do not co-produce an ESBL. Therefore, any 
Enterobacteriaceae isolate with a decreased 
carbapenem susceptibility may potentially 
be considered for screening.[17] Furthermore, 
a study of OXA-48-producer-infected mice 
has shown that ertapenem and imipenem 
failed to cure the rodents, even though the 
MIC values were low.[26] This is concerning, 
as OXA-48 was the predominant genotype 
in our sample population, indicating that 
isolates are not presenting as possible 
carriers of carbapenemases using routine 
diagnostic methods. A previous report in 
Enterobacteriaceae with reduced suscepti-
bility to at least one carbapenem has shown 
that increased resistance to temocillin (MIC 
>64 mg/mL) and pipercillin-tazo bactam 
may assist in identifying possible OXA-48 
producers.[27] Other phenotypic tests include 
the modified Hodge test (MHT), which 
is able to detect carbapenemase producers 
and works well for the detection of KPCs 
and OXA-48 but is less sensitive to NDM 
producers.[17] However, it is improved if zinc 
is included in the culture medium.[28] The 
MHT often lacks specificity, particularly 
in the presence of high-level AmpC- or 
cefotaxime-type ESBL producers, and it is 
time-consuming, requiring 24 - 48 hours. [17] 
Inhibition of ethylenediamintetra-acetic 
acid (EDTA) may be used for identifying 
MBLs, e.g. the Etest MBL strip (bioMérieux, 
UK). Imipenem and imipenem/EDTA are 
efficient for this purpose, particularly if the 
MBL producers exhibit high-level resistance, 
but may be problematic for low-level 
MBL producers. Other inhibitors include 
boronic acid, specific for KPC detection 
in K. pneumoniae when performed with 
impenem or meropenem. These phenotypic 
tests may be efficient in detecting some 
carbapenemases, but false-positive results 
can be obtained, particularly in AmpC 
producers.[17] It is therefore necessary to 
define an appropriate screening phenotypic 
method that is both reliable and accurate.
In a previous study, we showed the 
MicroScan Walkaway system coupled 
with the CLSI MIC breakpoint ranges as a 
method of carbapenemase production to 
have a high sensitivity (98%) and a low 
specificity (13%) using ertapenem.[29] From 
our results in the present study, using CLSI 
MIC breakpoint ranges for ertapenem, 157 
(57.3%) (Table 2) carbapenemase-producing 
isolates were not detected as carbapenemase 
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Fig. 1. Distribution of organism and carbapenemase types.
Proteus spp.: OXA-48, n=4; NDM, n=1
Raoultella spp.: NDMs, n=2; VIM, n=1
Morganella morganii: OXA-48, n=1; NDMs, n=11
Providencia spp.: OXA-48, n=2; NDMs, n=42; VIM, n=1; IMPs, n=2
Citrobacter spp.: OXA-48, n=14; NDMs, n=43; GES, n=1; KPCs, n=4
Serratia marcescens: OXA-48, n=34; NDMs, n=85; VIM, n=1; GESs, n=4
Escherichia coli: OXA-48, n=117; NDMs, n=25; VIM, n=1
Enterobacter spp.: OXA-48, n=94; NDMs, n=72; VIMs, n=12; GESs, n=31; KPCs, n=3
Klebsiella spp.: OXA-48, n=712; NDMs, n=623; VIMs, n=92; IMPs, n=2; GESs, n=19; KPCs, n=11
(MBLs = metallo-beta-lactamases; NDMs = New Delhi MBLs; VIMs = Verona integron-encoded 
MBLs; IMPs = imipenemases; GESs = Guiana extended-spectrum beta-lactamases; KPCs = Klebsiella 
pneumoniae carbapenemases.)
498       June 2018, Vol. 108, No. 6
RESEARCH
producers, contributing to false-negative results. The remaining 
antibiotics displayed a higher number of false negatives when 
both the CLSI[19] and EUCAST[20] MIC clinical breakpoint ranges 
were applied. Another study has shown ertapenem to be a good 
indicator for carbapenemase production, as the MICs are usually 
higher than those of the other carbapenems; however, they have 
also shown the specificity to be problematic.[17] In 2015, Maurer 
et al.[16] showed that CLSI clinical breakpoints for ertapenem and 
meropenem non-susceptibility displayed lower sensitivity than 
the EUCAST recommendation. Nevertheless, as recommended by 
EUCAST and published reports, CLSI and EUCAST guideline 
clinical breakpoints are sufficient for making treatment decisions, 
while carbapenemase detection and confirmation is recommended 
for epidemiological and infection prevention and control 
purposes. [17,20] The latter can be achieved by making use of EUCAST 
epidemiological cut-off values, which are considerably lower than 
the clinical breakpoints and detect early resistance.[14] The EUCAST 
guidelines for detection of resistance mechanisms and specific 
Table 2. MIC breakpoint values for the cephalosporins and carbapenems and CLSI guideline clinical breakpoint[19] interpretation
Antimicrobial agent
MIC  
(mg/mL) NDMs
OXA-48 and 
variants VIMs GESs IMPs KPCs Total
Cefotaxime ≤1 7 148 2 - - - 209
2 - 9 - - - - 15
4 - 16 - 1 1 - 21
8 1 9 1 - - - 13
16 4 10 - - - - 23
32 11 18 3 2 1 - 45
>32 881 768 102 21 33 18 2 352
Ceftazidime ≤1 7 162 2 - 1 - 227
2 - 11 - 1 - - 17
4 2 7 - 1 - - 17
8 - 19 - 1 - - 29
16 3 88 2 2 - - 117
>16 892 691 104 19 34 18 2 271
Cefepime ≤1 8 168 2 1 1 - 260
2 2 20 1 - - - 32
4 4 14 - - 2 - 41
8 12 21 2 2 4 - 65
16 16 60 9 2 5 - 106
>16 862 695 94 19 23 18 2 174
Ertapenem ≤0.5 13 128 12 3 1 - 274
1 11 195 21 3 - 324
>1 727 608 57 13 6 10 1 721
2 - 8 4 7 39
4 4 20 10 1 9 2 56
>4 149 19 4 7 9 6 264
Imipenem ≤1 35 634 8 2 8 1 1 050
≤2 40 157 14 4 20 1 429
4 70 40 58 2 2 3 201
8 274 45 15 2 1 5 356
>8 485 102 13 14 4 8 642
Meropenem ≤1 34 659 27 3 27 1 1 150
2 18 77 15 1 1 - 169
4 49 60 21 1 2 - 216
8 82 38 27 1 2 4 205
>8 721 144 18 18 3 13 938
Doripenem Not tested: 
not included 
in panel
155 52 24 9 26 8 428
≤1 29 669 16 2 8 1 1 072
2 28 56 14 - - - 155
4 49 54 12 1 1 2 164
>4 643 147 42 12 7 859
MIC = minimal inhibitory concentration; CLSI = Clinical and Laboratory Standards Institute; MBLs = metallo-beta-lactamases; NDMs = New Delhi MBLs; VIMs = Verona integron-encoded 
MBLs; GESs = Guiana extended-spectrum beta-lactamases; IMPs = imipenemases; KPCs = Klebsiella pneumoniae carbapenemases.
The white fields indicate the susceptible MIC breakpoint values according to CLSI breakpoints and the number of carbapenemase-producing isolates that would have been missed.
CLSI breakpoints: cefepime: ≤2 = susceptible, 4 - 8 = susceptible – dose dependent, ≥16 = resistant; cefotaxime: ≤1 = susceptible, 2 = intermediate, ≥4 = resistant; ceftazidime: ≤4 = susceptible,  
8 = intermediate, ≥16 = resistant; ertapenem: ≤0.5 = susceptible, 1 = intermediate, ≥2 = resistant; imipenem/meropenem/doripenem: ≤1 = susceptible, 2 = intermediate, ≥4 = resistant.[19]
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resistances of clinical and/or epidemiological importance[14,30] state 
that neither ertapenem nor imipenem are ideal agents, as ertapenem 
has a high sensitivity and low specificity and imipenem should not 
be used as a stand-alone screening agent because the separation 
between wild-type (i.e. susceptible) organisms and carbapenemase 
producers is poor. Meropenem is the recommended agent because 
it has the best compromise between sensitivity and specificity. This 
recommendation was further reiterated in a 2016 study by Fattouh 
et al.[15] investigating the meropenem MIC distribution profile 
of a large number of Enterobacteriaceae isolates with reduced 
susceptibility to carbapenems. They showed that based on CLSI and 
EUCAST clinical breakpoint interpretive criteria, 14% and 20% of 
carbapenemase producers, respectively, displayed MICs within the 
susceptible range, while 86% and 98.4% of carbapenemase-producing 
isolates were identified using the CLSI and EUCAST screening 
recommendations, respectively.[15] Screening recommendations are 
Table 3. MIC breakpoint values for the cephalosporins and carbapenems and EUCAST guideline clinical breakpoint[20] 
interpretation
Antimicrobial agent
MIC  
(mg/mL) NDMs
OXA-48 and 
variants VIMs GESs IMPs KPCs Total
Cefotaxime ≤1 7 148 2 - - - 209
2 - 9 - - - - 15
4 - 16 - 1 1 - 21
8 1 9 1 - - - 13
16 4 10 - - - - 23
32 11 18 3 2 1 - 45
>32 881 768 102 21 33 18 2 352
Ceftazidime ≤1 7 162 2 - 1 - 227
2 - 11 - 1 - - 17
4 2 7 - 1 - - 17
8 - 19 - 1 - - 29
16 3 88 2 2 - - 117
>16 892 691 104 19 34 18 2 271
Cefepime ≤1 8 168 2 1 1 - 260
2 2 20 1 - - - 32
4 4 14 - - 2 - 41
8 12 21 2 2 4 - 65
16 16 60 9 2 5 - 106
>16 862 695 94 19 23 18 2 174
Ertapenem ≤0.5 13 128 12 3 1 - 274
1 11 195 21 3 - 324
>1 727 608 57 13 6 10 1 721
2 - 8 4 7 39
4 4 20 10 1 9 2 56
>4 149 19 4 7 9 6 264
Imipenem ≤1 35 634 8 2 8 1 1 050
≤2 40 157 14 4 20 1 429
4 70 40 58 2 2 3 201
8 274 45 15 2 1 5 356
>8 485 102 13 14 4 8 642
Meropenem ≤1 34 659 27 3 27 1 1 150
2 18 77 15 1 1 - 169
4 49 60 21 1 2 - 216
8 82 38 27 1 2 4 205
>8 721 144 18 18 3 13 938
Doripenem Not tested: 
not included 
in panel
155 52 24 9 26 8 428
≤1 29 669 16 2 8 1 1 072
2 28 56 14 - - - 155
4 49 54 12 1 1 2 164
>4 643 147 42 12 7 859
MIC = minimal inhibitory concentration; EUCAST = European Committee on Antimicrobial Susceptibility Testing; MBLs = metallo-beta-lactamases; NDMs = New Delhi MBLs;  
VIMs = Verona integron-encoded MBLs; GESs = Guiana extended-spectrum beta-lactamases; IMPs = imipenemases; KPCs = Klebsiella pneumoniae carbapenemases.
The white fields indicate the susceptible MIC breakpoint values according to EUCAST breakpoints and the number of carbapenemase-producing isolates that would have been missed.
EUCAST clinical breakpoints: cefepime: ≤1 = susceptible, >4 = resistant; cefotaxime: ≤1 = susceptible, >2 = resistant; ceftazidime: ≤1 = susceptible, >4 = resistant; ertapenem: ≤0.5 = susceptible, 
>1 = resistant; imipenem/meropenem: ≤2 = susceptible, >8 resistant; doripenem: ≤1 = susceptible, >2 = resistant.[20]
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therefore recommended as the preferred 
guideline for epidemiological and infection 
prevention and control purposes, as they 
detect carbapenemase producers exhibiting 
low MICs; this means that lower MIC 
dilutions would need to be included for 
screening, and this poses a limitation in 
the current study. In order for us to be able 
to do this, dilutions lower than the lowest 
MIC dilution are required for analysis, and 
this was not achievable using the automated 
MicroScan Walkaway system. Although the 
number of missed carbapenemase-produ-
cing isolates would have been reduced 
and consequently the least number of 
CPE isolates would be misidentified as 
epidemiologically susceptible, the exact 
numbers could therefore not be quantified. 
Serial broth microdilution methods are the 
ideal and recommended method of choice. 
However, this method is tedious and requires 
expertise, as antibiotic concentrations and 
dilutions need to be extremely precise and 
accurate. An epidemiological cut-off value 
for meropenem of 0.125 mg/mL as endorsed 
by EUCAST[14] maximises CPE detection 
and is therefore the recommended approach; 
however, this is only feasible in a region 
with low carbapenemase prevalence[15] and 
is therefore not ideal in our settings owing 
to the high number of OXA-48- and NDM-
producing Enterobacteriaceae. Molecular 
methods are more accurate for the detection 
of carbapenemases, but they too require 
expertise and are expensive.[31]
EUCAST recommends that following the 
routine detection of reduced carbapenem 
susceptibility, additional phenotypic methods 
for the detection of carbapenemases should 
be applied.[14] Combination disc tests (CDTs) 
are discs or tablets with a carbapenem and 
various inhibitors. Inhibitors such as boronic 
acid and dipicolinic acid inhibit class A and 
class B carbapenemases, respectively. The 
AmpC beta-lactamase inhibitor cloxacillin 
has been included to differentiate between 
AmpC hyperproduction plus porin loss 
and carbapenemase production. As class 
D (OXA-48) inhibitors have not been 
included in phenotypic panels, resistance 
to piperacillin/tazobactam and high-level 
resistance to temocillin (MIC >128 mg/mL) 
can be used as phenotypic markers.[14] In a 
2015 study[16] aiming to develop a diagnostic 
flowchart using phenotypic screening and 
confirmation tests for clinical laboratories, 
the disc diffusion method using meropenem 
as the antimicrobial agent of choice was 
favoured for screening, as automated 
microdilution AST methods lack sensitivity 
and specificity. The authors support their 
findings by the fact that disc diffusion is 
cheap and simple to perform and can be 
implemented by many laboratories for 
routine AST. For confirmation of carbapene-
mases, Maurer et al.[16] explored several 
options for the various carbapenemases and 
conclusively decided that a combination of 
the EUCAST meropenem screening cut-
off of <28 mm or MIC >0.125 mg/mL[14] 
and ertapenem (or meropenem) amino-
phenyl boronic acid and EDTA CDTs 
plus temocillin disc diffusion (or gradient 
diffusion-based MIC determination) on 
Mueller-Hinton agar containing cloxacillin 
showed promise. Considering these publi-
shed recommendations and the South 
African Society for Clinical Microbiology’s 
current recommendation of a shift towards 
implementing the use of EUCAST guidelines 
in our SA setting, we have adapted the 
proposed diagnostic flowchart from Maurer 
et al.[16] and the EUCAST recommendations 
using EUCAST guidelines[14] for use in 
routine, academic, reference and national 
reference laboratories (Fig. 2). This would 
assist in the identification and detection 
of CPE for both clinical management and 
infection prevention and control purposes.
Enterobacteriaceae isolates
Meropenem zone diameter <28 mm or MIC >0.125 mg/mL
LE
VE
L 
III
Meropenem 25 - 27 mm 
and piperacillin/tazobactam
 intermediate susceptible
No 
carbapenemase 
suspected
No 
carbapenemase 
suspected
CDT ertapenem/meropenem* 
and ertapenem/meropenem*/APBA 
on MH-CLX agar
Dierence between 
ertapenem/meropenem*/APBA 
and ertapenem/meropenem* <5 mm
CDT ertapenem/meropenem* 
and ertapenem/meropenem*
 EDTA on MH agar
Dierence between 
ertapenem/
meropenem*/APBA 
and ertapenem/
meropenem* ≥5 mm
Dierence between 
ertapenem/
meropenem*/EDTA 
and ertapenem/
meropenem* <5 mm
Carbapenemases
Class A            Not suspected
Class B                Suspected
Class D                        ?
Carbapenemases
Class A             Suspected
Class B             Suspected
Class D                       ?
Carbapenemases
Class A              Suspected
Class B          Not suspected
Class D                       ?
Carbapenemases
CDT ertapenem/meropenem* 
and ertapenem/meropenem* 
EDTA on MH agar
Dierence between
 ertapenem/meropenem*
/EDTA and ertapenem/
meropenem* ≥5 mm
Dierence between 
ertapenem/meropenem*/
EDTA and ertapenem/
meropenem* ≥5 mm
Dierence between 
ertapenem/meropenem*/
EDTA and ertapenem/
meropenem* <5 mm
Class A          Not suspected
Class B          Not suspected
Class D                     ?
To screen for OXA-48-like
 producers
Temocillin disc diusion or
 MIC on MH-CLX agar
<11 mm or
>128 mg/mL
≥11 mm or
≤128 mg/mL
OXA-48-like 
enzyme
 suspected
OXA-48-like 
enzyme 
not suspected
Perform molecular assay 
for detection and conrmation 
of carbapenemase
LE
VE
L 
I
LE
VE
L 
II
No
Yes
Fig. 2. Diagnostic flow chart for detection of carbapenemases in Enterobacteriaceae, adapted 
from Maurer et al.[16] and the European Committee on Antimicrobial Susceptibility Testing[14] 
recommendations. Level I indicates processes to be performed at routine laboratories, level II indicates 
processes to be performed at academic and reference laboratories, and level III indicates processes 
to be performed at the national reference laboratory. (MIC = minimal inhibitory concentration; 
CDT  = combined disc test; APBA = aminophenyl boronic acid; MH = Mueller-Hinton agar; MH-
CLX = Mueller-Hinton agar containing cloxacillin; EDTA = ethylenediaminetetra-acetic acid. 
*Note: meropenem is known to have a lower sensitivity.)
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Conclusions
We have shown an increase in carbapenemase-producing 
Enterobacteriaceae over the study period. While phenotypic methods 
are acceptable for routine diagnosis, clinicians should be aware 
that carbapenemase-producing isolates are being misidentified as 
carbapenem-susceptible owing to limitations in routine phenotypic 
methodology. The application of CLSI and EUCAST clinical 
breakpoints, although suitable for clinical management, is not ideal 
for public health and infection prevention and control purposes; 
the use of epidemiological cut-off values is more appropriate for the 
latter. However, this is only fitting for use in a region with low CPE 
prevalence. A comprehensive CPE phenotypic screening method 
should be implemented to streamline isolates for molecular testing, 
which is relatively expensive.
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